EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.“Understanding whether [therapeutic drug monitoring (TDM)] would improve ownership of patient health decisions is important,” Charlotte L.M. Krieckaert, MD, of the Amsterdam Rheumatology and Immunology Center, and co-authors wrote in the Annals of the Rheumatic Diseases. “Equally, many rheumatologists are unaware of the pharmacokinetic properties of biopharmaceuticals andRead More

Categories: News

Related Articles

Patients with autoimmune disease receiving ICI exhibit better survival vs. controls

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year…

September 1, 2022

Let’s Talk About Physician Burnout

Physician Burnout has become a serious topic of discussion in the healthcare field lately. With such a large array of factors affecting the well-being…

Justin Bouck June 5, 2018

2019 Telehealth Bill

In 2019, Florida passed the Telehealth Bill which establishes standards of practice for telehealth services, including patient evaluations, record-keeping, and controlled substances prescribing. The bill…

Justin Bouck July 9, 2019

1-year surveillance endoscopy recommended for patients at high risk for gastric cancer

Patients at high risk for gastric cancer should undergo 1-year surveillance endoscopy, regardless of whether they initially underwent intensive index endoscopic examination using white light…

September 21, 2022

Early-life dog ownership may protect against development of Crohn’s disease

SAN DIEGO — Dog ownership and close interactions with these pets in early childhood could help prevent later development of Crohn’s disease, according to data…